Ra Capital Management, L.p. bought $8.8M of MLYS
director at Mineralys Therapeutics, Inc.. 369,000 shares at an average of $23.75, traded Mar 27, 2026, filed Mar 31, 2026.
Score components
- +15RoleDirector
- +25Trade size$8.8M at market
- +3Relative to holdingsHoldings up 7%
- +8Price context50% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -38% over 3 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-000300, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +310,700 | $23.67 | $7.4M | 5,767,221 | Mar 31, 2026 |
| Mar 30, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +58,300 | $24.16 | $1.4M | 5,825,521 | Mar 31, 2026 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 417 shares | -1% | |
| 4Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $543k 20,406 shares | -23% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $58k 2,171 shares | -3% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $12k 417 shares | -1% | |
| 9Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $570k 20,404 shares | -36% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $66k 2,171 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.